EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases

Somy Yoon, Gwang Hyeon Eom

Chonnam Medical Journal · 2016 · 52 (1) · 1

DOI: 10.4068/cmj.2016.52.1.1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Chonnam Medical Journal, 2016. Verfasst von Somy Yoon und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Chonnam National University Medical School, Gwangju, Korea. Die Arbeit wurde bisher 421-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) are epigenetic regulators that regulate the histone tail, chromatin conformation, protein-DNA interaction, and even transcription. HDACs are also post-transcriptional modifiers that regulate the protein acetylation implicated in several pathophysiologic states. HDAC inhibitors have been highlighted as a novel category of anti-cancer drugs. To date, four HDAC inhibitors, Vorinostat, Romidepsin, Panobinostat, and Belinostat, have been approved by the United States Food and Drug Administration. Principally, these HDAC inhibitors are used for hematologic cancers in clinic with less severe side effects. Clinical trials are continuously expanding to address other types of cancer and also nonmalignant diseases. HDAC inhibition also results in beneficial outcomes in various types of neurodegenerative diseases, inflammation disorders, and cardiovascular diseases. In this review, we will briefly discuss 1) the roles of HDACs in the acquisition of a cancer's phenotype and the general outcome of the HDAC inhibitors in cancer, 2) the functional relevance of HDACs in cardiovascular diseases and the possible therapeutic implications of HDAC inhibitors in cardiovascular disease.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular diseasesHistone deacetylase inhibitorsHistone deacetylasesNeoplasms

Autor:innen und Institutionen

  • Department of Pharmacology, Chonnam National University Medical School, Gwangju, Korea.

Zitieren

APA

Yoon, S., & Eom, G. H. (2016). HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Medical Journal, 52(1), 1. https://doi.org/10.4068/cmj.2016.52.1.1

Vancouver

Yoon S, Eom GH. HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Medical Journal. 2016;52(1):1. doi:10.4068/cmj.2016.52.1.1

BibTeX
@article{Yoon2016,
  author = {Yoon, Somy and Eom, Gwang Hyeon},
  title = {HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases},
  journal = {Chonnam Medical Journal},
  year = {2016},
  volume = {52},
  number = {1},
  pages = {1},
  doi = {10.4068/cmj.2016.52.1.1}
}
Kostenlos starten →